Keytruda + Lenvima demonstrate long-term survival benefit vs. sunitinib as first-line RCC treatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

After four years of follow-up, Keytruda (pembrolizumab) plus Lenvima (lenvatinib) maintained a clinically meaningful overall survival benefit versus sunitinib in the phase III CLEAR (Study 307)/KEYNOTE-581 trial of first-line treatment in patients with advanced renal cell carcinoma. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Iovance Biotherapeutics Inc. a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, has updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting. 
The phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival for the first-line treatment of patients with human epidermal growth factor receptor 2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Login